<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">40152336</PMID><DateCompleted><Year>2025</Year><Month>06</Month><Day>12</Day></DateCompleted><DateRevised><Year>2025</Year><Month>06</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1530-0358</ISSN><JournalIssue CitedMedium="Internet"><Volume>68</Volume><Issue>7</Issue><PubDate><Year>2025</Year><Month>Jul</Month><Day>01</Day></PubDate></JournalIssue><Title>Diseases of the colon and rectum</Title><ISOAbbreviation>Dis Colon Rectum</ISOAbbreviation></Journal><ArticleTitle>Difference in the Prognostic Benefit Between Extended and Segmental Colectomy for Patients With Neoplasia Associated With Ulcerative Colitis: A Nationwide Multicenter Study.</ArticleTitle><Pagination><StartPage>855</StartPage><EndPage>864</EndPage><MedlinePgn>855-864</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/DCR.0000000000003662</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Extended colectomy is considered a standard treatment for neoplasia associated with ulcerative colitis, but there is limited supporting evidence, particularly from large-scale studies.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">This study aimed to assess the prognostic benefits of extended colectomy in patients with neoplasia associated with ulcerative colitis using a nationwide database.</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">Multicenter retrospective study.</AbstractText><AbstractText Label="SETTINGS" NlmCategory="METHODS">Forty-three institutions in Japan participated in this study.</AbstractText><AbstractText Label="PATIENTS" NlmCategory="METHODS">The medical records of patients with ulcerative colitis and diagnosed intestinal neoplasia between 1983 and 2020 at 43 institutions were analyzed.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES" NlmCategory="METHODS">Five-year overall survival and disease-free survival were assessed on the basis of different surgical procedures, with a subgroup analysis comparing neoplasia associated with ulcerative colitis to sporadic cancer.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Among 879 patients, 801 were diagnosed with neoplasia associated with ulcerative colitis and 78 with sporadic cancer. The 5-year disease-free survival for total proctocolectomy and subtotal colectomy were similar (87.8% and 83.9%), and both were superior to segmental colectomy (72.0%). When comparing neoplasia associated with ulcerative colitis to sporadic cancer, extended colectomy (total proctocolectomy and subtotal colectomy) showed significantly better outcomes for neoplasia associated with ulcerative colitis, whereas no significant difference was observed for sporadic cancer. Multivariable analysis revealed a significantly better prognosis for extended colectomy compared to segmental colectomy in neoplasia associated with patients with ulcerative colitis, both in overall survival and disease-free survival ( p &lt; 0.001).</AbstractText><AbstractText Label="LIMITATION" NlmCategory="CONCLUSIONS">Nonrandomized retrospective study design.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">This nationwide cohort study supports extended colectomy as the criterion standard for neoplasia associated with ulcerative colitis management and underscores the importance of accurate diagnosis to distinguish between neoplasia associated with ulcerative colitis and sporadic cancer for optimal treatment decisions. See Video Abstract.</AbstractText><AbstractText Label="DIFERENCIA EN EL BENEFICIO PRONSTICO ENTRE LA COLECTOMA EXTENDIDA Y SEGMENTARIA PARA PACIENTES CON NEOPLASIA ASOCIADA A COLITIS ULCERATIVA UN ESTUDIO MULTICNTRICO A NIVEL NACIONAL" NlmCategory="UNASSIGNED">ANTECEDENTES:La colectom&#xed;a extendida se considera el tratamiento est&#xe1;ndar para la neoplasia asociada con la colitis ulcerativa, pero hay evidencia de respaldo limitada, particularmente de estudios a gran escala.OBJETIVO:Este estudio tuvo como objetivo evaluar los beneficios pron&#xf3;sticos de la colectom&#xed;a extendida en pacientes con neoplasia asociada con colitis ulcerativa utilizando una base de datos nacional.DISE&#xd1;O:Estudio retrospectivo multic&#xe9;ntrico.ESCENARIO:Cuarenta y tres instituciones en Jap&#xf3;n participaron en este estudio.PACIENTES:Se analizaron pacientes con colitis ulcerativa diagnosticados con neoplasia intestinal entre 1983 y 2020 en 43 instituciones.PRINCIPALES MEDIDAS DE RESULTADOS:Se evaluaron la supervivencia general a cinco a&#xf1;os y la supervivencia libre de enfermedad en funci&#xf3;n de diferentes procedimientos quir&#xfa;rgicos, con un an&#xe1;lisis de subgrupos que comparaba la neoplasia asociada con colitis ulcerativa con el c&#xe1;ncer espor&#xe1;dico.RESULTADOS:Entre 879 pacientes, 801 fueron diagnosticados con neoplasia asociada con colitis ulcerativa y 78 con c&#xe1;ncer espor&#xe1;dico. La supervivencia libre de enfermedad a 5 a&#xf1;os para la proctocolectom&#xed;a total y la colectom&#xed;a subtotal fue similar (87,8% y 83,9%), ambas superiores a la colectom&#xed;a segmentaria (72,0%). Al comparar la neoplasia asociada a la colitis ulcerativa con el c&#xe1;ncer espor&#xe1;dico, la colectom&#xed;a extendida (proctocolectom&#xed;a total y colectom&#xed;a subtotal) mostr&#xf3; resultados significativamente mejores para la neoplasia asociada a la colitis ulcerativa, mientras que no se observ&#xf3; una diferencia significativa para el c&#xe1;ncer espor&#xe1;dico. El an&#xe1;lisis multivariable revel&#xf3; un pron&#xf3;stico significativamente mejor para la colectom&#xed;a extendida en comparaci&#xf3;n con la colectom&#xed;a segmentaria en pacientes con neoplasia asociada a la colitis ulcerativa, tanto en la supervivencia general como en la supervivencia libre de enfermedad (p &lt; 0,001).LIMITACI&#xd3;N:Dise&#xf1;o de estudio retrospectivo no aleatorizado.CONCLUSI&#xd3;N:Este estudio de cohorte a nivel nacional respalda la colectom&#xed;a extendida como el est&#xe1;ndar de oro para el manejo de la neoplasia asociada a la colitis ulcerativa y subraya la importancia de un diagn&#xf3;stico preciso para distinguir entre la neoplasia asociada a la colitis ulcerativa y el c&#xe1;ncer espor&#xe1;dico para tomar decisiones &#xf3;ptimas de tratamiento. (Traducci&#xf3;n- Dr. Francisco M. Abarca-Rendon ).</AbstractText><CopyrightInformation>Copyright &#xa9; The ASCRS 2025.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Seishima</LastName><ForeName>Ryo</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0002-4837-4832</Identifier><AffiliationInfo><Affiliation>Department of Surgery, Keio University School of Medicine, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Okabayashi</LastName><ForeName>Koji</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Surgery, Keio University School of Medicine, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Okui</LastName><ForeName>Jun</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Surgery, Keio University School of Medicine, Tokyo, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Preventive Medicine and Public Health, Keio University School of Medicine, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sato</LastName><ForeName>Yasunori</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Preventive Medicine and Public Health, Keio University School of Medicine, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Noguchi</LastName><ForeName>Tatsuki</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Surgical Oncology, University of Tokyo, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sugihara</LastName><ForeName>Kenichi</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Tokyo Medical and Dental University, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ajioka</LastName><ForeName>Yoichi</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Division of Molecular and Diagnostic Pathology, Graduate School of Medical and Dental Sciences, Niigata University, Niigata, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ishihara</LastName><ForeName>Soichiro</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Surgical Oncology, University of Tokyo, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>Study Group for Inflammatory Bowel Disease-Associated Intestinal Cancers of the Japanese Society for Cancer of the Colon and Rectum*</CollectiveName></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D059040">Video-Audio Media</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>03</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Dis Colon Rectum</MedlineTA><NlmUniqueID>0372764</NlmUniqueID><ISSNLinking>0012-3706</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003093" MajorTopicYN="Y">Colitis, Ulcerative</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003082" MajorTopicYN="Y">Colectomy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007564" MajorTopicYN="N" Type="Geographic">Japan</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018572" MajorTopicYN="N">Disease-Free Survival</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Extended colectomy</Keyword><Keyword MajorTopicYN="N">Neoplasia associated with ulcerative colitis</Keyword><Keyword MajorTopicYN="N">Sporadic colorectal cancer</Keyword></KeywordList><InvestigatorList><Investigator ValidYN="Y"><LastName>Seishima</LastName><ForeName>Ryo</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Okabayashi</LastName><ForeName>Koji</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Okui</LastName><ForeName>Jun</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sato</LastName><ForeName>Yasunori</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ikeuchi</LastName><ForeName>Hiroki</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Uchino</LastName><ForeName>Motoi</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Futami</LastName><ForeName>Kitaro</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Noguchi</LastName><ForeName>Tatsuki</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ohge</LastName><ForeName>Hiroki</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Iseki</LastName><ForeName>Yasuihito</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Watanabe</LastName><ForeName>Kazuhiro</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Itabashi</LastName><ForeName>Michio</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Okamoto</LastName><ForeName>Kinya</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Okita</LastName><ForeName>Yoshiki</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ogino</LastName><ForeName>Takayuki</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nakamura</LastName><ForeName>Masafumi</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Yamada</LastName><ForeName>Kazutaka</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wakai</LastName><ForeName>Toshifumi</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sato</LastName><ForeName>Yu</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kimura</LastName><ForeName>Hideaki</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Takahashi</LastName><ForeName>Kenichi</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hida</LastName><ForeName>Koya</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kinugasa</LastName><ForeName>Yusuke</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ishida</LastName><ForeName>Fumio</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Okuda</LastName><ForeName>Junji</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Daito</LastName><ForeName>Koji</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Koyama</LastName><ForeName>Fumikazu</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ueno</LastName><ForeName>Hideki</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Yamamoto</LastName><ForeName>Takayuki</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Yamamoto</LastName><ForeName>Seiichiro</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hanai</LastName><ForeName>Tsunekazu</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Maemoto</LastName><ForeName>Atsuo</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Arakaki</LastName><ForeName>Junya</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Komori</LastName><ForeName>Koji</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fujita</LastName><ForeName>Fumihiko</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shida</LastName><ForeName>Dai</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Yamaguchi</LastName><ForeName>Shigeki</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Matsuda</LastName><ForeName>Keiji</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Maeda</LastName><ForeName>Kiyoshi</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Noake</LastName><ForeName>Toshihiro</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nezu</LastName><ForeName>Riichiro</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sasaki</LastName><ForeName>Shin</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hasegawa</LastName><ForeName>Junichi</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sunami</LastName><ForeName>Eiji</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kanemitsu</LastName><ForeName>Yukihide</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Katsumata</LastName><ForeName>Kenji</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Uehara</LastName><ForeName>Kay</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kiyomatsu</LastName><ForeName>Tomomichi</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Suto</LastName><ForeName>Takeshi</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kazama</LastName><ForeName>Shinsuke</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Yamada</LastName><ForeName>Takeshi</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Goi</LastName><ForeName>Takanori</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ishihara</LastName><ForeName>Soichiro</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ajioka</LastName><ForeName>Yoichi</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sugihara</LastName><ForeName>Kenichi</ForeName><Initials>K</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>6</Month><Day>12</Day><Hour>12</Hour><Minute>31</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>3</Month><Day>28</Day><Hour>12</Hour><Minute>32</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>3</Month><Day>28</Day><Hour>8</Hour><Minute>3</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40152336</ArticleId><ArticleId IdType="doi">10.1097/DCR.0000000000003662</ArticleId><ArticleId IdType="pii">00003453-202507000-00012</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut. 2001;48:526&#x2013;535.</Citation></Reference><Reference><Citation>Jess T, Rungoe C, Peyrin-Biroulet L. Risk of colorectal cancer in patients with ulcerative colitis: a meta-analysis of population-based cohort studies. Clin Gastroenterol Hepatol. 2012;10:639&#x2013;645.</Citation></Reference><Reference><Citation>Watanabe T, Konishi T, Kishimoto J, Kotake K, Muto T, Sugihara K; Japanese Society for Cancer of the Colon and Rectum. Ulcerative colitis-associated colorectal cancer shows a poorer survival than sporadic colorectal cancer: a nationwide Japanese study. Inflamm Bowel Dis. 2011;17:802&#x2013;808.</Citation></Reference><Reference><Citation>Leowardi C, Schneider ML, Hinz U, et al. Prognosis of ulcerative colitis-associated colorectal carcinoma compared to sporadic colorectal carcinoma: a matched pair analysis. Ann Surg Oncol. 2016;23:870&#x2013;876.</Citation></Reference><Reference><Citation>Sato Y, Tsujinaka S, Miura T, Kitamura Y, Suzuki H, Shibata C. Inflammatory bowel disease and colorectal cancer: epidemiology, etiology, surveillance, and management. Cancers (Basel). 2023;15:4154.</Citation></Reference><Reference><Citation>Andersson P, Soderholm JD. Surgery in ulcerative colitis: indication and timing. Dig Dis. 2009;27:335&#x2013;340.</Citation></Reference><Reference><Citation>Rubin DT, Ananthakrishnan AN, Siegel CA, Sauer BG, Long MD. ACG clinical guideline: ulcerative colitis in adults. Am J Gastroenterol. 2019;114:384&#x2013;413.</Citation></Reference><Reference><Citation>Annese V, Beaugerie L, Egan L, et al.; ECCO. European evidence-based consensus: inflammatory bowel disease and malignancies. J Crohns Colitis. 2015;9:945&#x2013;965.</Citation></Reference><Reference><Citation>Khan N, Cole E, Shah Y, Paulson EC. Segmental resection is a safe oncological alternative to total proctocolectomy in elderly patients with ulcerative colitis and malignancy. Colorectal Dis. 2017;19:1108&#x2013;1116.</Citation></Reference><Reference><Citation>Mohan BP, Khan SR, Chandan S, et al. Endoscopic resection of colon dysplasia in patients with inflammatory bowel disease: a systematic review and meta-analysis. Gastrointest Endosc. 2021;93:59&#x2013;67.e10.</Citation></Reference><Reference><Citation>Bogach J, Pond G, Eskicioglu C, Simunovic M, Seow H. Extent of surgical resection in inflammatory bowel disease associated colorectal cancer: a population-based study. J Gastrointest Surg. 2021;25:2610&#x2013;2618.</Citation></Reference><Reference><Citation>Noguchi T, Ishihara S, Uchino M, et al.; Study Group for Inflammatory Bowel Disease Associated Intestinal Cancers by the Japanese Society for Cancer of the Colon, Rectum. Clinical features and oncological outcomes of intestinal cancers associated with ulcerative colitis and Crohn&#x2019;s disease. J Gastroenterol. 2023;58:14&#x2013;24.</Citation></Reference><Reference><Citation>Mizuuchi Y, Nagayoshi K, Nakamura M, et al.; Study Group for Inflammatory Bowel Disease-Associated Intestinal Cancers of the Japanese Society for Cancer of the Colon and Rectum. Prognostic impact of tumour location in stage II/III ulcerative colitis-associated colon cancer: subgroup analysis of a nationwide multicentre retrospective study in Japan. Br J Surg. 2024;111:znad386.</Citation></Reference><Reference><Citation>Krugliak Cleveland N, Ollech JE, Colman RJ, et al. Efficacy and follow-up of segmental or subtotal colectomy in patients with colitis-associated neoplasia. Clin Gastroenterol Hepatol. 2019;17:205&#x2013;206.</Citation></Reference><Reference><Citation>Sugita A, Ikeuchi H, Funayama Y, et al. Postoperative survival in colitis-associated colorectal cancer with ulcerative colitis in Japan: a multicenter analysis. Anticancer Res. 2021;41:2681&#x2013;2688.</Citation></Reference><Reference><Citation>Kiran RP, Khoury W, Church JM, Lavery IC, Fazio VW, Remzi FH. Colorectal cancer complicating inflammatory bowel disease: similarities and differences between Crohn&#x2019;s and ulcerative colitis based on three decades of experience. Ann Surg. 2010;252:330&#x2013;335.</Citation></Reference><Reference><Citation>Seishima R, Okabayashi K, Ikeuchi H, et al. Effect of biologics on the risk of advanced-stage inflammatory bowel disease-associated intestinal cancer: a nationwide study. Am J Gastroenterol. 2023;118:1248&#x2013;1255.</Citation></Reference><Reference><Citation>Horio Y, Uchino M, Hori K, et al. Clinical features and therapeutic outcomes of post-colectomy enteritis with ulcerative colitis. J Anus Rectum Colon. 2021;5:405&#x2013;413.</Citation></Reference><Reference><Citation>Ihara K, Nakamura T, Takayanagi M, et al. Risk factors for stoma outlet obstruction after proctocolectomy for ulcerative colitis. J Anus Rectum Colon. 2024;8:18&#x2013;23.</Citation></Reference><Reference><Citation>Mutaguchi M, Naganuma M, Sugimoto S, et al. Difference in the clinical characteristic and prognosis of colitis-associated cancer and sporadic neoplasia in ulcerative colitis patients. Dig Liver Dis. 2019;51:1257&#x2013;1264.</Citation></Reference><Reference><Citation>Birch RJ, Burr N, Subramanian V, et al. Inflammatory bowel disease-associated colorectal cancer epidemiology and outcomes: an English population-based study. Am J Gastroenterol. 2022;117:1858&#x2013;1870.</Citation></Reference><Reference><Citation>Derks ME, Te Groen M, Peters CP, et al.; Dutch Initiative on Crohn and Colitis. Endoscopic and surgical treatment outcomes of colitis-associated advanced colorectal neoplasia: a multicenter cohort study. Int J Surg. 2023;109:1961&#x2013;1969.</Citation></Reference><Reference><Citation>Yilmaz S, Gunter RL, Kanters AE, et al. Segmental colectomy in ulcerative colitis. Dis Colon Rectum. 2024;67:1048&#x2013;1055.</Citation></Reference><Reference><Citation>Lindberg J, Stenling R, Palmqvist R, Ruteg&#xe5;rd J. Surgery for neoplastic changes in ulcerative colitis&#x2014;can limited resection be justified? Outcome for patients who underwent limited surgery. Colorectal Dis. 2006;8:551&#x2013;556.</Citation></Reference><Reference><Citation>Abd El Aziz MA, Perry WRG, Grass F, et al. The extent of colorectal resection and short-term outcomes in patients with ulcerative colitis. Updates Surg. 2021;73:1429&#x2013;1434.</Citation></Reference><Reference><Citation>Shah SC, Itzkowitz SH. Colorectal cancer in inflammatory bowel disease: mechanisms and management. Gastroenterology. 2022;162:715&#x2013;730.e3.</Citation></Reference><Reference><Citation>Yantiss RK, Odze RD. Diagnostic difficulties in inflammatory bowel disease pathology. Histopathology. 2006;48:116&#x2013;132.</Citation></Reference><Reference><Citation>Vandenbroucke JP, von EE, Altman DG, et al. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. Int J Surg. 2014;12:1500&#x2013;1524.</Citation></Reference><Reference><Citation>Concato J, Shah N, Horwitz RI. Randomized, controlled trials, observational studies, and the hierarchy of research designs. N Engl J Med. 2000;342:1887&#x2013;1892.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37787557</PMID><DateCompleted><Year>2023</Year><Month>12</Month><Day>16</Day></DateCompleted><DateRevised><Year>2025</Year><Month>07</Month><Day>24</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1530-0358</ISSN><JournalIssue CitedMedium="Internet"><Volume>67</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Jan</Month><Day>01</Day></PubDate></JournalIssue><Title>Diseases of the colon and rectum</Title><ISOAbbreviation>Dis Colon Rectum</ISOAbbreviation></Journal><ArticleTitle>Anal Cancers in Previously Screened Versus Unscreened Patients: Tumor Stage and Treatment Outcomes.</ArticleTitle><Pagination><StartPage>32</StartPage><EndPage>41</EndPage><MedlinePgn>32-41</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/DCR.0000000000002922</ELocationID><Abstract><AbstractText Label="BACKGROUND">Targeted screening programs for patients at high risk for anal squamous-cell carcinoma have been proposed; however, the evidence in support of screening remains unclear.</AbstractText><AbstractText Label="OBJECTIVE">This study aimed to determine whether screening high-risk patients (predominantly those living with HIV) detected squamous-cell carcinoma at an earlier stage compared to the routine practice of not screening.</AbstractText><AbstractText Label="DESIGN">This is a cohort study.</AbstractText><AbstractText Label="SETTINGS">This study was conducted at a quaternary care center in Canada.</AbstractText><AbstractText Label="PATIENTS">Included patients were at least 18 years old with a pathologic diagnosis of invasive anal squamous-cell carcinoma between 2002 and 2022.</AbstractText><AbstractText Label="INTERVENTIONS">Patients diagnosed through a high-risk screening program were compared to those who did not undergo screening.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES">The primary outcome was clinical stage at presentation, categorized as T1N0M0 vs other. Secondary outcomes included treatments received, treatment failure, and overall survival.</AbstractText><AbstractText Label="RESULTS">A total of 612 patients with anal squamous-cell carcinoma were included, with 26 of those patients diagnosed through a screening program. Patients with screen-detected cancers had greater odds of presenting with T1N0M0 tumors compared to unscreened patients (18 [69.2%] vs 84 [14.3%]; adjusted OR 9.95; 95% CI, 3.95-25.08). A propensity score-matched sensitivity analysis found similar results (OR 11.13; 95% CI, 4.67-26.52). Screened patients had greater odds of treatment with wide local excision alone, as opposed to any combination of chemotherapy, radiation therapy, and surgery (3 [12.5%] vs 18 [3.2%]; OR 4.38; 95% CI, 1.20-16.04). There were no statistically significant differences in treatment failure or overall survival between groups.</AbstractText><AbstractText Label="LIMITATIONS">The small number of screened patients limits the power of the analysis.</AbstractText><AbstractText Label="CONCLUSIONS">Screening for anal squamous-cell carcinoma among high-risk populations detects cancers at an earlier stage. Patients with screen-detected cancers also had a greater likelihood of being candidates for wide local excision alone, which may have spared them the morbidity associated with chemoradiotherapy or abdominoperineal resection. See Video Abstract.</AbstractText><AbstractText Label="CNCERES DE ANO EN PACIENTES PREVIAMENTE DETECTADOS POR CRIBADO VERSUS NO DETECTADOS ESTADIO DEL TUMOR Y RESULTADOS DEL TRATAMIENTO">ANTECEDENTES:Se han propuesto programas de cribado dirigidos a pacientes con alto riesgo de carcinoma anal de c&#xe9;lulas escamosas; sin embargo, la evidencia a favor de la detecci&#xf3;n sigue sin estar clara.OBJETIVO:Este estudio tuvo como objetivo determinar si el cribado de pacientes de alto riesgo (predominantemente aquellos que viven con el VIH) detect&#xf3; el carcinoma de c&#xe9;lulas escamosas en una etapa m&#xe1;s temprana en comparaci&#xf3;n con la pr&#xe1;ctica habitual de no cribado.DISE&#xd1;O:Este es un estudio de cohortes.CONFIGURACI&#xd3;N:Este estudio se realiz&#xf3; en un centro de atenci&#xf3;n cuaternaria en Canad&#xe1;.PACIENTES:Los pacientes incluidos ten&#xed;an al menos 18 a&#xf1;os con un diagn&#xf3;stico patol&#xf3;gico de carcinoma de c&#xe9;lulas escamosas anal invasivo entre 2002 y 2022.INTERVENCIONES:Los pacientes diagnosticados mediante un programa de cribado de alto riesgo se compararon con aquellos que no se sometieron a cribado.PRINCIPALES MEDIDAS DE RESULTADO:El resultado primario fue el estadio cl&#xed;nico en la presentaci&#xf3;n, categorizado como T1N0M0 versus otro. Los resultados secundarios incluyeron los tratamientos recibidos, el fracaso del tratamiento y la supervivencia general.RESULTADOS:Se incluyeron un total de 612 pacientes con carcinoma anal de c&#xe9;lulas escamosas, con 26 de esos pacientes diagnosticados a trav&#xe9;s de un programa de cribado. Los pacientes con c&#xe1;nceres detectados mediante cribado ten&#xed;an mayores probabilidades de presentar tumores T1N0M0 en comparaci&#xf3;n con los pacientes no cribados (18 [69.2%] frente a 84 [14.3%]; raz&#xf3;n de probabilidad ajustada 9.95; intervalo de confianza del 95 % 3.95 -25.08). Un an&#xe1;lisis de sensibilidad emparejado por puntaje de propensi&#xf3;n encontr&#xf3; resultados similares (odds ratio 11.13; intervalo de confianza del 95% 4.67 -26.52; p &lt; 0.001). Los pacientes examinados ten&#xed;an mayores probabilidades de recibir tratamiento con escisi&#xf3;n local amplia sola, en comparaci&#xf3;n con cualquier combinaci&#xf3;n de quimioterapia, radiaci&#xf3;n y cirug&#xed;a (3 [12.5%] frente a 18 [3.2%]; raz&#xf3;n de probabilidad 4.38; intervalo de confianza del 95 % 1.20 -16.04). No hubo diferencias estad&#xed;sticamente significativas en el fracaso del tratamiento o la supervivencia global entre los grupos.LIMITACIONES:El peque&#xf1;o n&#xfa;mero de pacientes evaluados limita el poder del an&#xe1;lisis.CONCLUSIONES:La detecci&#xf3;n del carcinoma anal de c&#xe9;lulas escamosas entre las poblaciones de alto riesgo detecta los c&#xe1;nceres en una etapa m&#xe1;s temprana. Los pacientes con c&#xe1;nceres detectados mediante cribado tambi&#xe9;n ten&#xed;an una mayor probabilidad de ser candidatos para una escisi&#xf3;n local amplia sola, lo que puede haberles evitado la morbilidad asociada con la quimiorradioterapia o la resecci&#xf3;n abdominoperineal. (Traducci&#xf3;n --Dr. Aurian Garcia Gonzalez ).</AbstractText><CopyrightInformation>Copyright &#xa9; The ASCRS 2023.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Walker</LastName><ForeName>Richard J B</ForeName><Initials>RJB</Initials><AffiliationInfo><Affiliation>Department of Surgery, University Health Network, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of General Surgery, Department of Surgery, University of Toronto, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Easson</LastName><ForeName>Alexandra M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Department of Surgery, University Health Network, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of General Surgery, Department of Surgery, University of Toronto, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Surgical Oncology, Mount Sinai Hospital, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hosni</LastName><ForeName>Ali</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Radiation Oncology, University of Toronto, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Radiation Medicine Program, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>John</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Radiation Oncology, University of Toronto, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Radiation Medicine Program, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weiss</LastName><ForeName>Edward S</ForeName><Initials>ES</Initials><AffiliationInfo><Affiliation>Department of Medicine, University Health Network, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Santiago</LastName><ForeName>Anna T</ForeName><Initials>AT</Initials><AffiliationInfo><Affiliation>Department of Biostatistics, University Health Network, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chesney</LastName><ForeName>Tyler R</ForeName><Initials>TR</Initials><AffiliationInfo><Affiliation>Division of General Surgery, Department of Surgery, University of Toronto, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Surgery, St. Michael's Hospital, Unity Health Toronto, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Li Ka Shing Knowledge Institute, St. Michael's Hospital, Unity Health Toronto, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Salit</LastName><ForeName>Irving E</ForeName><Initials>IE</Initials><AffiliationInfo><Affiliation>Department of Medicine, University Health Network, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D059040">Video-Audio Media</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>09</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Dis Colon Rectum</MedlineTA><NlmUniqueID>0372764</NlmUniqueID><ISSNLinking>0012-3706</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001005" MajorTopicYN="Y">Anus Neoplasms</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002294" MajorTopicYN="Y">Carcinoma, Squamous Cell</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009367" MajorTopicYN="N">Neoplasm Staging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012004" MajorTopicYN="Y">Rectal Neoplasms</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>12</Month><Day>17</Day><Hour>9</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>10</Month><Day>3</Day><Hour>12</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>10</Month><Day>3</Day><Hour>9</Hour><Minute>12</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37787557</ArticleId><ArticleId IdType="doi">10.1097/DCR.0000000000002922</ArticleId><ArticleId IdType="pii">00003453-202401000-00007</ArticleId></ArticleIdList><ReferenceList><Title/><Reference><Citation>NIH. National Cancer Institute. Surveillance, Epidemiology, and End Results Program. Cancer stat facts: anal cancer. https://seer.cancer.gov/statfacts/html/anus.html . Published 2022.</Citation></Reference><Reference><Citation>Clifford GM, Georges D, Shiels MS, et al. A meta-analysis of anal cancer incidence by risk group: toward a unified anal cancer risk scale. Int J Cancer. 2021;148:38&#x2013;47.</Citation></Reference><Reference><Citation>Palefsky JM. Screening to prevent anal cancer: current thinking and future directions. Cancer Cytopathol. 2015;123:509&#x2013;510.</Citation></Reference><Reference><Citation>Clarke MA, Wentzensen N. Strategies for screening and early detection of anal cancers: a narrative and systematic review and meta-analysis of cytology, HPV testing, and other biomarkers. Cancer Cytopathol. 2018;126:447&#x2013;460.</Citation></Reference><Reference><Citation>Crum-Cianflone NF, Hullsiek KH, Marconi VC, et al.; Infectious Disease Clinical Research Program HIV Working Group. Anal cancers among HIV-infected persons: HAART is not slowing rising incidence. AIDS. 2010;24:535&#x2013;543.</Citation></Reference><Reference><Citation>Machalek DA, Poynten M, Jin F, et al. Anal human papillomavirus infection and associated neoplastic lesions in men who have sex with men: a systematic review and meta-analysis. Lancet Oncol. 2012;13:487&#x2013;500.</Citation></Reference><Reference><Citation>Daling JR, Madeleine MM, Johnson LG, et al. Human papillomavirus, smoking, and sexual practices in the etiology of anal cancer. Cancer. 2004;101:270&#x2013;280.</Citation></Reference><Reference><Citation>Adami J, G&#xe4;bel H, Lindel&#xf6;f B, et al. Cancer risk following organ transplantation: a nationwide cohort study in Sweden. Br J Cancer. 2003;89:1221&#x2013;1227.</Citation></Reference><Reference><Citation>Edgren G, Spar&#xe9;n P. Risk of anogenital cancer after diagnosis of cervical intraepithelial neoplasia: a prospective population-based study. Lancet Oncol. 2007;8:311&#x2013;316.</Citation></Reference><Reference><Citation>Stewart DB, Gaertner WB, Glasgow SC, Herzig DO, Feingold D, Steele SR; prepared on behalf of the Clinical Practice Guidelines Committee of the American Society of Colon and Rectal Surgeons. The American Society of Colon and Rectal Surgeons clinical practice guidelines for anal squamous cell cancers (revised 2018). Dis Colon Rectum. 2018;61:755&#x2013;774.</Citation></Reference><Reference><Citation>Binda GA, Gagliardi G, Dal Conte I, et al. Practice parameters for the diagnosis and treatment of anal intraepithelial neoplasia (AIN) on behalf of the Italian Society of Colorectal Surgery (SICCR). Tech Coloproctol. 2019;23:513&#x2013;528.</Citation></Reference><Reference><Citation>Glynne-Jones R, Nilsson PJ, Aschele C, et al.; ESMO. Anal cancer: ESMO-ESSO-ESTRO clinical practice guidelines for diagnosis, treatment and follow-up. Radiother Oncol. 2014;111:330&#x2013;339.</Citation></Reference><Reference><Citation>Berenson AB, Guo F, Chang M. Association of human papillomavirus vaccination with the incidence of squamous cell carcinomas of the anus in the US. JAMA Oncol. 2022;8:1&#x2013;3.</Citation></Reference><Reference><Citation>Hillman RJ, Berry-Lawhorn JM, Ong JJ, et al.; International Anal Neoplasia Society. International Anal Neoplasia Society guidelines for the practice of digital anal rectal examination. J Low Genit Tract Dis. 2019;23:138&#x2013;146.</Citation></Reference><Reference><Citation>Milan&#xe9;s Guisado Y, Sotomayor C, Fontill&#xf3;n M, et al.; SeVIHanal Study Group. Incidence rate and risk factors for anal squamous cell carcinoma in a cohort of people living with HIV from 2004 to 2017: implementation of a screening program. Dis Colon Rectum. 2022;65:28&#x2013;39.</Citation></Reference><Reference><Citation>Revollo B, Videla S, Llibre JM, et al. Routine screening of anal cytology in persons with human immunodeficiency virus and the impact on invasive anal cancer: a prospective cohort study. Clin Infect Dis. 2020;71:390&#x2013;399.</Citation></Reference><Reference><Citation>Lee JY, Lensing SY, Berry-Lawhorn JM, et al.; ANCHOR Investigators. Design of the ANal Cancer/HSIL Outcomes Research study (ANCHOR study): a randomized study to prevent anal cancer among persons living with HIV. Contemp Clin Trials. 2022;113:106679.</Citation></Reference><Reference><Citation>Palefsky JM, Lee JY, Jay N, et al.; ANCHOR Investigators Group. Treatment of anal high-grade squamous intraepithelial lesions to prevent anal cancer. N Engl J Med. 2022;386:2273&#x2013;2282.</Citation></Reference><Reference><Citation>Amin MB, Edge S, Greene F, et al, eds. AJCC Cancer Staging Manual. 8th ed. Springer International Publishing; 2017. https://www.springer.com/gp/book/9783319406176 . Accessed May 9, 2021.</Citation></Reference><Reference><Citation>Chai CY, Tran Cao HS, Awad S, Massarweh NN. Management of stage I squamous cell carcinoma of the anal canal. JAMA Surg. 2018;153:209&#x2013;215.</Citation></Reference><Reference><Citation>National Comprehensive Cancer Network. Anal carcinoma https://www.nccn.org/professionals/physician_gls/pdf/anal.pdf . Published 2022.</Citation></Reference><Reference><Citation>Clarke TC, Soler-Vila H, Fleming LE, Christ SL, Lee DJ, Arheart KL. Trends in adherence to recommended cancer screening: the US population and working cancer survivors. Front Oncol. 2012;2:190.</Citation></Reference><Reference><Citation>Paepke D, Wiedeck C, Hapfelmeier A, Kiechle M, Brambs C. Lifestyle modifications after the diagnosis of gynecological cancer. BMC Womens Health. 2021;21:260.</Citation></Reference><Reference><Citation>Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999;94:496&#x2013;509.</Citation></Reference><Reference><Citation>Nigro ND, Seydel HG, Considine B, Vaitkevicius VK, Leichman L, Kinzie JJ. Combined preoperative radiation and chemotherapy for squamous cell carcinoma of the anal canal. Cancer. 1983;51:1826&#x2013;1829.</Citation></Reference><Reference><Citation>James RD, Glynne-Jones R, Meadows HM, et al. Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2&#x2009;&#xd7;&#x2009;2 factorial trial. Lancet Oncol. 2013;14:516&#x2013;524.</Citation></Reference><Reference><Citation>Ng SSM, Leung KL, Lee JFY, et al. Laparoscopic-assisted versus open abdominoperineal resection for low rectal cancer: a prospective randomized trial. Ann Surg Oncol. 2008;15:2418&#x2013;2425.</Citation></Reference><Reference><Citation>N&#xe4;svall P, Dahlstrand U, L&#xf6;wenmark T, Ruteg&#xe5;rd J, Gunnarsson U, Strig&#xe5;rd K. Quality of life in patients with a permanent stoma after rectal cancer surgery. Qual Life Res. 2017;26:55&#x2013;64.</Citation></Reference><Reference><Citation>Berry JM, Jay N, Cranston RD, et al. Progression of anal high-grade squamous intraepithelial lesions to invasive anal cancer among HIV-infected men who have sex with men. Int J Cancer. 2014;134:1147&#x2013;1155.</Citation></Reference><Reference><Citation>Kahi CJ, Imperiale TF, Juliar BE, Rex DK. Effect of screening colonoscopy on colorectal cancer incidence and mortality. Clin Gastroenterol Hepatol. 2009;7:770&#x2013;5; quiz 711.</Citation></Reference><Reference><Citation>Surveillance, Epidemiology, and End Results Program. Cancer stat facts: female breast cancer. https://seer.cancer.gov/statfacts/html/breast.html . Published 2023.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">31490827</PMID><DateCompleted><Year>2019</Year><Month>11</Month><Day>25</Day></DateCompleted><DateRevised><Year>2020</Year><Month>06</Month><Day>03</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1530-0358</ISSN><JournalIssue CitedMedium="Internet"><Volume>62</Volume><Issue>10</Issue><PubDate><Year>2019</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Diseases of the colon and rectum</Title><ISOAbbreviation>Dis Colon Rectum</ISOAbbreviation></Journal><ArticleTitle>Guideline-Recommended Chemoradiation for Patients With Rectal Cancer at Large Hospitals: A Trend in the Right Direction.</ArticleTitle><Pagination><StartPage>1186</StartPage><EndPage>1194</EndPage><MedlinePgn>1186-1194</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/DCR.0000000000001452</ELocationID><Abstract><AbstractText Label="BACKGROUND">Many patients with rectal cancer are treated at small, low-volume hospitals despite evidence that better outcomes are associated with larger, high-volume hospitals.</AbstractText><AbstractText Label="OBJECTIVES">This study aims to examine trends of patients with rectal cancer who are receiving care at large hospitals, to determine the patient characteristics associated with treatment at large hospitals, and to assess the relationships between treatment at large hospitals and guideline-recommended therapy.</AbstractText><AbstractText Label="DESIGN">This study was a retrospective cohort analysis to assess trends in rectal cancer treatment.</AbstractText><AbstractText Label="SETTINGS">Data from the National Cancer Institute's Surveillance, Epidemiology, and End Results Patterns of Care studies were used.</AbstractText><AbstractText Label="PATIENTS">The study population consisted of adults diagnosed with stages II/III rectal cancer in 1990/1991, 1995, 2000, 2005, 2010, and 2015.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES">The primary outcome was treatment at large hospitals (&#x2265;500 beds). The receipt of guideline-recommended preoperative chemoradiation therapy and postoperative chemotherapy was assessed for patients diagnosed in 2005+.</AbstractText><AbstractText Label="RESULTS">Two thousand two hundred thirty-one patients were included. The proportion treated at large hospitals increased from 19% in 1990/1991 to 27% in 2015 (ptrend &lt; 0.0001). Black race was associated with treatment at large hospitals (vs white) (OR, 1.73; 95% CI, 1.30-2.31), as was being 55 to 64 years of age (vs 75+), and diagnosis in 2015 (vs 1990/1991). Treatment in large hospitals was associated with twice the odds of preoperative chemoradiation, as well as younger age and diagnosis in 2010 or 2015 (vs 2005).</AbstractText><AbstractText Label="LIMITATIONS">The study did not account for the change in the number of large hospitals over time.</AbstractText><AbstractText Label="CONCLUSIONS">Results suggest that patients with rectal cancer are increasingly being treated in large hospitals where they receive more guideline-recommended therapy. Although this trend is promising, patients receiving care at larger, higher-volume facilities are still the minority. Initiatives increasing patient and provider awareness of benefits of specialized care, as well as increasing referrals to large centers may improve the use of recommended treatment and ultimately improve outcomes. See Video Abstract at http://links.lww.com/DCR/A994. QUIMIORRADIACI&#xd3;N RECOMENDADA EN GU&#xcd;AS PARA PACIENTES CON C&#xc1;NCER RECTAL EN HOSPITALES DE GRAN TAMA&#xd1;O: UNA TENDENCIA EN LA DIRECCI&#xd3;N CORRECTA: Muchos pacientes con c&#xe1;ncer rectal se tratan en hospitales peque&#xf1;os y de bajo volumen a pesar de evidencia de que los mejores resultados se asocian con hospitales m&#xe1;s grandes y de gran volumen.</AbstractText><AbstractText Label="OBJETIVOS">Examinar las tendencias en los pacientes con c&#xe1;ncer rectal que reciben atenci&#xf3;n en hospitales de gran tama&#xf1;o, determinar las caracter&#xed;sticas de los pacientes asociadas con el tratamiento en hospitales grandes y evaluar la relaci&#xf3;n entre el tratamiento en hospitales grandes y la terapia recomendada en gu&#xed;as. DISE&#xd1;O:: Este estudio fue un an&#xe1;lisis de cohorte retrospectivo para evaluar las tendencias en el tratamiento del c&#xe1;ncer de recto.</AbstractText><AbstractText Label="ESCENARIO">Se utilizaron datos de los estudios del programa Patrones de Atenci&#xf3;n, Vigilancia, Epidemiolog&#xed;a y Resultados Finales (SEER) del Instituto Nacional de C&#xe1;ncer (NIH).</AbstractText><AbstractText Label="PACIENTES">La poblaci&#xf3;n de estudio consisti&#xf3; en adultos diagnosticados con c&#xe1;ncer rectal en estadio II / III en 1990/1991, 1995, 2000, 2005, 2010 y 2015.</AbstractText><AbstractText Label="PRINCIPALES MEDIDAS DE RESULTADO">El resultado primario fue el tratamiento en hospitales grandes (&#x2265;500 camas). La recepci&#xf3;n de quimiorradiaci&#xf3;n preoperatoria recomendada seg&#xfa;n las gu&#xed;as y la quimioterapia posoperatoria se evaluaron para los pacientes diagnosticados en 2005 y posteriormente.</AbstractText><AbstractText Label="RESULTADOS">Se incluyeron 2,231 pacientes. La proporci&#xf3;n tratada en los hospitales grandes aument&#xf3; del 19% en 1990/1991 al 27% en 2015 (ptrend &lt; 0.0001). La raza afroamericana se asoci&#xf3; con el tratamiento en hospitales grandes (vs. blanca) (OR, 1.73; IC 95%, 1.30-2.31), al igual que 55-64 a&#xf1;os de edad (vs &#x2265;75) y diagn&#xf3;stico en 2015 (vs 1990/1991). El tratamiento en los hospitales grandes se asoci&#xf3; con el doble de probabilidad de quimiorradiaci&#xf3;n preoperatoria, as&#xed; como con una edad m&#xe1;s temprana y diagn&#xf3;stico en 2010 o 2015 (vs 2005).</AbstractText><AbstractText Label="LIMITACIONES">El estudio no tom&#xf3; en cuenta el cambio en el n&#xfa;mero de hospitales grandes a lo largo del tiempo.</AbstractText><AbstractText Label="CONCLUSIONES">Los resultados sugieren que los pacientes con c&#xe1;ncer rectal reciben cada vez m&#xe1;s tratamiento en hospitales grandes donde reciben terapia recomendada por las gu&#xed;as mas frecuentemente. Aunque esta tendencia es prometedora, los pacientes que reciben atenci&#xf3;n en hospitales m&#xe1;s grandes y de mayor volumen siguen siendo una minor&#xed;a. Las iniciativas que aumenten la concientizaci&#xf3;n del paciente y del proveedor de servicios m&#xe9;dicos sobre los beneficios de la atenci&#xf3;n especializada, as&#xed; como el aumento de las referencias a centros grandes podr&#xed;an mejorar el uso del tratamiento recomendado y, en &#xfa;ltima instancia, mejorar los resultados. Vea el Resumen en video en http://links.lww.com/DCR/A994.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Del Vecchio</LastName><ForeName>Natalie J</ForeName><Initials>NJ</Initials><AffiliationInfo><Affiliation>Department of Epidemiology, University of Iowa College of Public Health, Iowa City, Iowa.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schlichting</LastName><ForeName>Jennifer A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Department of Epidemiology, University of Iowa College of Public Health, Iowa City, Iowa.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chioreso</LastName><ForeName>Catherine</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Epidemiology, University of Iowa College of Public Health, Iowa City, Iowa.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kahl</LastName><ForeName>Amanda R</ForeName><Initials>AR</Initials><AffiliationInfo><Affiliation>Iowa Cancer Registry, University of Iowa College of Public Health, Iowa City, Iowa.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hrabe</LastName><ForeName>Jennifer E</ForeName><Initials>JE</Initials><AffiliationInfo><Affiliation>Department of Surgery, University of Iowa Carver College of Medicine, Iowa City, Iowa.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lynch</LastName><ForeName>Charles F</ForeName><Initials>CF</Initials><AffiliationInfo><Affiliation>Department of Epidemiology, University of Iowa College of Public Health, Iowa City, Iowa.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Iowa Cancer Registry, University of Iowa College of Public Health, Iowa City, Iowa.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>West</LastName><ForeName>Michele M</ForeName><Initials>MM</Initials><AffiliationInfo><Affiliation>Iowa Cancer Registry, University of Iowa College of Public Health, Iowa City, Iowa.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Charlton</LastName><ForeName>Mary E</ForeName><Initials>ME</Initials><AffiliationInfo><Affiliation>Department of Epidemiology, University of Iowa College of Public Health, Iowa City, Iowa.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>HHSN261201000032C</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>HHSN261201300020I</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 CA086862</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D059040">Video-Audio Media</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Dis Colon Rectum</MedlineTA><NlmUniqueID>0372764</NlmUniqueID><ISSNLinking>0012-3706</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000970" MajorTopicYN="N">Antineoplastic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D059248" MajorTopicYN="N">Chemoradiotherapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D061847" MajorTopicYN="N">Hospitals, High-Volume</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009367" MajorTopicYN="Y">Neoplasm Staging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017410" MajorTopicYN="N">Practice Guidelines as Topic</DescriptorName><QualifierName UI="Q000592" MajorTopicYN="Y">standards</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012004" MajorTopicYN="N">Rectal Neoplasms</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018426" MajorTopicYN="Y">SEER Program</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015996" MajorTopicYN="N">Survival Rate</DescriptorName><QualifierName UI="Q000639" MajorTopicYN="N">trends</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>9</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>9</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>11</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2020</Year><Month>6</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31490827</ArticleId><ArticleId IdType="mid">NIHMS1591281</ArticleId><ArticleId IdType="pmc">PMC7263440</ArticleId><ArticleId IdType="doi">10.1097/DCR.0000000000001452</ArticleId><ArticleId IdType="pii">00003453-201910000-00008</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014;64:9&#x2013;29.</Citation><ArticleIdList><ArticleId IdType="pubmed">24399786</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaertner WB, Kwaan MR, Madoff RD, Melton GB. Rectal cancer: An evidence-based update for primary care providers. World J Gastroenterol. 2015;21:7659&#x2013;7671.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4491955</ArticleId><ArticleId IdType="pubmed">26167068</ArticleId></ArticleIdList></Reference><Reference><Citation>Abbas MA, Chang GJ, Read TE, et al. Optimizing rectal cancer management: analysis of current evidence. Dis Colon Rectum. 2014;57:252&#x2013;259.</Citation><ArticleIdList><ArticleId IdType="pubmed">24401889</ArticleId></ArticleIdList></Reference><Reference><Citation>Richardson DP, Porter GA, Johnson PM. Surgeon knowledge contributes to the relationship between surgeon volume and patient outcomes in rectal cancer. Ann Surg. 2013;257:295&#x2013;301.</Citation><ArticleIdList><ArticleId IdType="pubmed">22968065</ArticleId></ArticleIdList></Reference><Reference><Citation>Benson AB 3rd, Venook AP, Al-Hawary MM, et al. Rectal Cancer, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2018;16:874&#x2013;901.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10203817</ArticleId><ArticleId IdType="pubmed">30006429</ArticleId></ArticleIdList></Reference><Reference><Citation>Charlton ME, Hrabe JE, Wright KB, et al. Hospital Characteristics Associated with Stage II/III Rectal Cancer Guideline Concordant Care: Analysis of Surveillance, Epidemiology and End Results-Medicare Data. J Gastrointest Surg. 2016;20:1002&#x2013;1011.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7332110</ArticleId><ArticleId IdType="pubmed">26658793</ArticleId></ArticleIdList></Reference><Reference><Citation>Birkmeyer JD, Sun Y, Wong SL, Stukel TA. Hospital volume and late survival after cancer surgery. Ann Surg. 2007;245:777&#x2013;783.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1877074</ArticleId><ArticleId IdType="pubmed">17457171</ArticleId></ArticleIdList></Reference><Reference><Citation>Begg CB, Cramer LD, Hoskins WJ, Brennan MF. Impact of hospital volume on operative mortality for major cancer surgery. JAMA. 1998;280:1747&#x2013;1751.</Citation><ArticleIdList><ArticleId IdType="pubmed">9842949</ArticleId></ArticleIdList></Reference><Reference><Citation>Pieper D, Mathes T, Neugebauer E, Eikermann M. State of evidence on the relationship between high-volume hospitals and outcomes in surgery: a systematic review of systematic reviews. J Am Coll Surg. 2013;216:1015&#x2013;1025 e1018.</Citation><ArticleIdList><ArticleId IdType="pubmed">23528183</ArticleId></ArticleIdList></Reference><Reference><Citation>Huo YR, Phan K, Morris DL, Liauw W. Systematic review and a meta-analysis of hospital and surgeon volume/outcome relationships in colorectal cancer surgery. J Gastrointest Oncol. 2017;8:534&#x2013;546.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5506277</ArticleId><ArticleId IdType="pubmed">28736640</ArticleId></ArticleIdList></Reference><Reference><Citation>Archampong D, Borowski DW, Dickinson HO. Impact of surgeon volume on outcomes of rectal cancer surgery: a systematic review and meta-analysis. Surgeon. 2010;8:341&#x2013;352.</Citation><ArticleIdList><ArticleId IdType="pubmed">20950774</ArticleId></ArticleIdList></Reference><Reference><Citation>Iversen LH, Harling H, Laurberg S, Wille-Jorgensen P. Influence of caseload and surgical speciality on outcome following surgery for colorectal cancer: a review of evidence. Part 1: short-term outcome. Colorectal dis. 2007;9:28&#x2013;37.</Citation><ArticleIdList><ArticleId IdType="pubmed">17181843</ArticleId></ArticleIdList></Reference><Reference><Citation>Birkmeyer JD, Siewers AE, Finlayson EV, et al. Hospital volume and surgical mortality in the United States. N Engl J Med. 2002;346:1128&#x2013;1137.</Citation><ArticleIdList><ArticleId IdType="pubmed">11948273</ArticleId></ArticleIdList></Reference><Reference><Citation>Salz T, Sandler RS. The effect of hospital and surgeon volume on outcomes for rectal cancer surgery. Clin Gastroenterol Hepatol. 2008;6:1185&#x2013;1193.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2582059</ArticleId><ArticleId IdType="pubmed">18829393</ArticleId></ArticleIdList></Reference><Reference><Citation>Hodgson DC, Zhang W, Zaslavsky AM, Fuchs CS, Wright WE, Ayanian JZ. Relation of hospital volume to colostomy rates and survival for patients with rectal cancer. J Natl Cancer Inst. 2003;95:708&#x2013;716.</Citation><ArticleIdList><ArticleId IdType="pubmed">12759388</ArticleId></ArticleIdList></Reference><Reference><Citation>Baek JH, Alrubaie A, Guzman EA, et al. The association of hospital volume with rectal cancer surgery outcomes. Int J Colorectal Dis. 2013;28:191&#x2013;196.</Citation><ArticleIdList><ArticleId IdType="pubmed">22842664</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith JA, King PM, Lane RH, Thompson MR. Evidence of the effect of &#x2018;specialization&#x2019; on the management, surgical outcome and survival from colorectal cancer in Wessex. Br J Surg. 2003;90:583&#x2013;592.</Citation><ArticleIdList><ArticleId IdType="pubmed">12734867</ArticleId></ArticleIdList></Reference><Reference><Citation>Marusch F, Koch A, Schmidt U, Pross M, Gastinger I, Lippert H. Hospital caseload and the results achieved in patients with rectal cancer. Br J Surg. 2001;88:1397&#x2013;1402.</Citation><ArticleIdList><ArticleId IdType="pubmed">11578299</ArticleId></ArticleIdList></Reference><Reference><Citation>Schrag D, Panageas KS, Riedel E, et al. Hospital and surgeon procedure volume as predictors of outcome following rectal cancer resection. Ann Surg. 2002;236:583&#x2013;592.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1422616</ArticleId><ArticleId IdType="pubmed">12409664</ArticleId></ArticleIdList></Reference><Reference><Citation>Harmon JW, Tang DG, Gordon TA, et al. Hospital volume can serve as a surrogate for surgeon volume for achieving excellent outcomes in colorectal resection. Ann Surg. 1999;230:404&#x2013;411; discussion 411&#x2013;403.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1420885</ArticleId><ArticleId IdType="pubmed">10493487</ArticleId></ArticleIdList></Reference><Reference><Citation>Billingsley KG, Morris AM, Green P, et al. Does surgeon case volume influence nonfatal adverse outcomes after rectal cancer resection? J Am Coll Surg. 2008;206:1167&#x2013;1177.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3103396</ArticleId><ArticleId IdType="pubmed">18501815</ArticleId></ArticleIdList></Reference><Reference><Citation>Nugent E, Neary P. Rectal cancer surgery: volume-outcome analysis. Int J Colorectal Dis. 2010;25:1389&#x2013;1396.</Citation><ArticleIdList><ArticleId IdType="pubmed">20661600</ArticleId></ArticleIdList></Reference><Reference><Citation>Paulson EC, Mitra N, Sonnad S, et al. National Cancer Institute designation predicts improved outcomes in colorectal cancer surgery. Ann Surg. 2008;248:675&#x2013;686.</Citation><ArticleIdList><ArticleId IdType="pubmed">18936581</ArticleId></ArticleIdList></Reference><Reference><Citation>Meyerhardt JA, Tepper JE, Niedzwiecki D, et al. Impact of hospital procedure volume on surgical operation and long-term outcomes in high-risk curatively resected rectal cancer: findings from the Intergroup 0114 Study. J Clin Oncol. 2004;22:166&#x2013;174.</Citation><ArticleIdList><ArticleId IdType="pubmed">14701779</ArticleId></ArticleIdList></Reference><Reference><Citation>Rogers SO Jr., Wolf RE, Zaslavsky AM, Wright WE, Ayanian JZ. Relation of surgeon and hospital volume to processes and outcomes of colorectal cancer surgery. Ann Surg. 2006;244:1003&#x2013;1011.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1856632</ArticleId><ArticleId IdType="pubmed">17122626</ArticleId></ArticleIdList></Reference><Reference><Citation>Smedh K, Olsson L, Johansson H, Aberg C, Andersson M. Reduction of postoperative morbidity and mortality in patients with rectal cancer following the introduction of a colorectal unit. Br J Surg. 2001;88:273&#x2013;277.</Citation><ArticleIdList><ArticleId IdType="pubmed">11167880</ArticleId></ArticleIdList></Reference><Reference><Citation>Borowski DW, Kelly SB, Bradburn DM, et al. Impact of surgeon volume and specialization on short-term outcomes in colorectal cancer surgery. Br J Surg. 2007;94:880&#x2013;889.</Citation><ArticleIdList><ArticleId IdType="pubmed">17410637</ArticleId></ArticleIdList></Reference><Reference><Citation>Purves H, Pietrobon R, Hervey S, Guller U, Miller W, Ludwig K. Relationship between surgeon caseload and sphincter preservation in patients with rectal cancer. Dis Colon Rectum. 2005;48:195&#x2013;202; discussion 202&#x2013;194.</Citation><ArticleIdList><ArticleId IdType="pubmed">15812583</ArticleId></ArticleIdList></Reference><Reference><Citation>Martling A, Cedermark B, Johansson H, Rutqvist LE, Holm T. The surgeon as a prognostic factor after the introduction of total mesorectal excision in the treatment of rectal cancer. Br J Surg. 2002;89:1008&#x2013;1013.</Citation><ArticleIdList><ArticleId IdType="pubmed">12153626</ArticleId></ArticleIdList></Reference><Reference><Citation>McGrath DR, Leong DC, Gibberd R, Armstrong B, Spigelman AD. Surgeon and hospital volume and the management of colorectal cancer patients in Australia. ANZ J Surg. 2005;75:901&#x2013;910.</Citation><ArticleIdList><ArticleId IdType="pubmed">16176237</ArticleId></ArticleIdList></Reference><Reference><Citation>Stitzenberg KB, Sigurdson ER, Egleston BL, Starkey RB, Meropol NJ. Centralization of cancer surgery: implications for patient access to optimal care. J Clin Oncol. 2009;27:4671&#x2013;4678.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3039919</ArticleId><ArticleId IdType="pubmed">19720926</ArticleId></ArticleIdList></Reference><Reference><Citation>Stitzenberg KB, Meropol NJ. Trends in centralization of cancer surgery. Ann Surg Oncol. 2010;17:2824&#x2013;2831.</Citation><ArticleIdList><ArticleId IdType="pubmed">20559740</ArticleId></ArticleIdList></Reference><Reference><Citation>Aquina CT, Probst CP, Becerra AZ, et al. High volume improves outcomes: The argument for centralization of rectal cancer surgery. Surgery. 2016;159:736&#x2013;748.</Citation><ArticleIdList><ArticleId IdType="pubmed">26576696</ArticleId></ArticleIdList></Reference><Reference><Citation>Collaborative Stage Work Group of the American Joint Committee on Cancer. Collaborative Stage Data Collection System Coding Instructions, version 02.00.00. Incorporates updates through January 1, 2010.</Citation></Reference><Reference><Citation>Institute of Medicine Committee on the Roles of Academic Health Centers in the 21st C. In: Kohn LT, ed. Academic Health Centers: Leading Change in the 21st Century. Washington (DC): National Academies Press (US) Copyright 2004 by the National Academy of Sciences; All rights reserved.; 2004.</Citation></Reference><Reference><Citation>Hamelinck VC, Bastiaannet E, Pieterse AH, van de Velde CJH, Liefers GJ, Stiggelbout AM. Preferred and Perceived Participation of Younger and Older Patients in Decision Making About Treatment for Early Breast Cancer: A Prospective Study. Clin Breast Cancer. 2018;18:e245&#x2013;253.</Citation><ArticleIdList><ArticleId IdType="pubmed">29275105</ArticleId></ArticleIdList></Reference><Reference><Citation>Caldwell JT, Ford CL, Wallace SP, Wang MC, Takahashi LM. Intersection of Living in a Rural Versus Urban Area and Race/Ethnicity in Explaining Access to Health Care in the United States. Am J Public Health. 2016;106:1463&#x2013;1469.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4940644</ArticleId><ArticleId IdType="pubmed">27310341</ArticleId></ArticleIdList></Reference><Reference><Citation>Stewart DB, Hollenbeak C, Desharnais S, et al. Rectal cancer and teaching hospitals: hospital teaching status affects use of neoadjuvant radiation and survival for rectal cancer patients. Ann Surg Oncol. 2013;20:1156&#x2013;1163.</Citation><ArticleIdList><ArticleId IdType="pubmed">23184292</ArticleId></ArticleIdList></Reference><Reference><Citation>National Cancer Institute Surveillance Epidemiology and End Results. POC Data Acquisition Manual 2010 Diagnosis: Breast Cancer, Non-Small Cell Lung Cancer, Colorectal Cancer. 2011.</Citation></Reference><Reference><Citation>Xu Z, Becerra AZ, Justiniano CF, et al. Is the Distance Worth It? Patients With Rectal Cancer Traveling to High-Volume Centers Experience Improved Outcomes. Dis Colon Rectum. 2017;60:1250&#x2013;1259.</Citation><ArticleIdList><ArticleId IdType="pubmed">29112560</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">27731538</PMID><DateCompleted><Year>2017</Year><Month>09</Month><Day>13</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>11</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1469-0705</ISSN><JournalIssue CitedMedium="Internet"><Volume>49</Volume><Issue>2</Issue><PubDate><Year>2017</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Ultrasound in obstetrics &amp; gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology</Title><ISOAbbreviation>Ultrasound Obstet Gynecol</ISOAbbreviation></Journal><ArticleTitle>Single-dose systemic methotrexate vs expectant management for&#x2009;treatment&#x2009;of&#x2009;tubal&#x2009;ectopic&#x2009;pregnancy:&#x2009;a&#x2009;placebo-controlled randomized trial.</ArticleTitle><Pagination><StartPage>171</StartPage><EndPage>176</EndPage><MedlinePgn>171-176</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/uog.17329</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Methotrexate is used routinely worldwide for the medical treatment of clinically stable women with a tubal ectopic pregnancy. This is despite the lack of robust evidence to show its superior effectiveness over expectant management. The aim of our multicenter randomized controlled trial was to compare success rates of methotrexate against placebo for the conservative treatment of tubal ectopic pregnancy.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">This study took place in two early-pregnancy units in the UK between August 2005 and June 2014. Inclusion criteria were clinically stable women with a conclusive ultrasound diagnosis of a tubal ectopic pregnancy, presenting with a low serum beta human chorionic gonadotropin (&#x3b2;-hCG) level of&#x2009;&lt;&#x2009;1500&#x2009;IU/L. Women were assigned randomly to a single systemic injection of either 50&#x2009;mg/m<sup>2</sup> methotrexate or placebo. The primary outcome was a binary indicator for success of conservative management, defined as resolution of clinical symptoms and decline of serum &#x3b2;-hCG to&#x2009;&lt;&#x2009;20&#x2009;IU/L or a negative urine pregnancy test without the need for any additional medical intervention. An intention-to-treat analysis was followed.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">We recruited a total of 80 women, 42 of whom were assigned to methotrexate and 38 to placebo. The arms of the study were matched in terms of age, ethnicity, obstetric history, pregnancy characteristics and serum levels of &#x3b2;-hCG and progesterone. The rates of success were similar for the two study arms: 83% with methotrexate and 76% with placebo. On univariate analysis, this difference was not statistically significant (&#x3c7;<sup>2</sup> (1 degree of freedom)&#x2009;=&#x2009;0.53; P&#x2009;=&#x2009;0.47). On multivariate logistic regression, the serum level of &#x3b2;-hCG was the only covariate found to be significantly associated with outcome. The odds of failure increased by 0.15% for each unit increase in &#x3b2;-hCG (odds ratio, 1.0015 (95% CI, 1.0002-1.003); P&#x2009;=&#x2009;0.02). In 14 women presenting with serum &#x3b2;-hCG of 1000-1500&#x2009;IU/L, the success rate was 33% in those managed expectantly compared with 62% in those receiving methotrexate. This difference was not statistically significant and a larger sample size would be needed to give sufficient power to detect a difference in the subgroup of women with higher &#x3b2;-hCG. In women with successful conservative treatment, there was no significant difference in median &#x3b2;-hCG resolution times between study arms (17.5 (interquartile range (IQR), 14-28.0) days (n&#x2009;=&#x2009;30) in the methotrexate group vs 14 (IQR, 7-29.5) days (n&#x2009;=&#x2009;25) in the placebo group; P&#x2009;=&#x2009;0.73).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The results of our study do not support the routine use of methotrexate for the treatment of clinically stable women diagnosed with tubal ectopic pregnancy presenting with low serum &#x3b2;-hCG (&lt;&#x2009;1500&#x2009;IU/L). Further work is required to identify a subgroup of women with tubal ectopic pregnancy and &#x3b2;-hCG &#x2265;&#x2009;1500&#x2009;IU/L in whom methotrexate may offer a safe and cost-effective alternative to surgery. Copyright &#xa9; 2016 ISUOG. Published by John Wiley &amp; Sons Ltd. Comparaci&#xf3;n entre una sola dosis de metotrexate sist&#xe9;mico y la conducta expectante en el tratamiento de casos de embarazo ect&#xf3;pico tub&#xe1;rico: un ensayo aleatorio controlado con placebo RESUMEN OBJETIVO: El metotrexate se utiliza de modo rutinario en todo el mundo para el tratamiento de las mujeres cl&#xed;nicamente estables con un embarazo ect&#xf3;pico tub&#xe1;rico. Esto sucede a pesar de la falta de evidencia rigurosa que demuestre que su eficacia es superior a la conducta expectante. El objetivo de este ensayo controlado aleatorio multic&#xe9;ntrico fue comparar las tasas de &#xe9;xito del metotrexate con las de un placebo para el tratamiento cauteloso del embarazo ect&#xf3;pico tub&#xe1;rico. M&#xc9;TODOS: Este estudio se llev&#xf3; a cabo en dos cl&#xed;nicas de control de gestaci&#xf3;n temprana en el Reino Unido entre agosto de 2005 y junio de 2014. Los criterios de inclusi&#xf3;n fueron mujeres cl&#xed;nicamente estables con un diagn&#xf3;stico ecogr&#xe1;fico concluyente de embarazo ect&#xf3;pico tub&#xe1;rico, las cu&#xe1;les presentaban una concentraci&#xf3;n s&#xe9;rica baja de la &#x3b2; hormona cori&#xf3;nica gonadotr&#xf3;pica (&#x3b2;-hCG) inferior a 1500 UI/L. Las mujeres fueron asignadas aleatoriamente a una sola inyecci&#xf3;n sist&#xe9;mica de 50&#x2009;mg/m2 de metotrexate o a placebo. El resultado primario fue un indicador binario del &#xe9;xito del tratamiento conservador, definido como la resoluci&#xf3;n de los s&#xed;ntomas cl&#xed;nicos y la disminuci&#xf3;n en el suero de la &#x3b2;-hCG a &lt;20 UI/L o una prueba de embarazo negativa en orina sin la necesidad de ninguna intervenci&#xf3;n m&#xe9;dica adicional. Se hizo un an&#xe1;lisis por intenci&#xf3;n de tratar.</AbstractText><AbstractText Label="RESULTADOS" NlmCategory="RESULTS">Se reclut&#xf3; un total de 80 mujeres; a 42 de ellas se les asign&#xf3; el metotrexate y a 38 el placebo. Los grupos del estudio se realizaron en funci&#xf3;n de la edad, el origen &#xe9;tnico, los antecedentes obst&#xe9;tricos, las caracter&#xed;sticas del embarazo y los niveles s&#xe9;ricos de la &#x3b2;-hCG y la progesterona. Las tasas de &#xe9;xito fueron similares para los dos grupos de estudio: 83% con metotrexate y 76% con placebo. En el an&#xe1;lisis univariante, esta diferencia no fue estad&#xed;sticamente significativa (&#x3c7;2 (1 grado de libertad)&#x2009;=&#x2009;0,53; P = 0,47). En la regresi&#xf3;n log&#xed;stica multivariante, el nivel s&#xe9;rico de la &#x3b2;-hCG fue la &#xfa;nica covariable que se encontr&#xf3; significativamente asociada con el resultado. Las probabilidades de fracaso aumentaron en un 0,15% por cada unidad de aumento de la &#x3b2;-hCG (cociente de probabilidad 1,0015 (IC 95%, 1,0002-1,003); P = 0,02). La tasa de &#xe9;xito en las 14 mujeres con un nivel s&#xe9;rico de la &#x3b2;-hCG de 1000-1500 UI/L fue del 33% en las tratadas con conducta expectante frente al 62% en las que recibieron metotrexate. Esta diferencia no fue estad&#xed;sticamente significativa, por lo que se necesitar&#xed;a un tama&#xf1;o de muestra mayor, lo suficiente como para poder detectar diferencias en el subgrupo de mujeres con una &#x3b2;-hCG m&#xe1;s elevada. En las mujeres en las que el tratamiento conservador tuvo &#xe9;xito, no hubo una diferencia significativa en la mediana de los tiempos de resoluci&#xf3;n de la &#xdf;-hCG entre los grupos del estudio (17,5 (amplitud intercuart&#xed;lica (IQR), 14-28,0) d&#xed;as (n = 30) en el grupo de metotrexate frente a 14 (IQR, 7-29.5) d&#xed;as (n = 25) en el grupo de placebo; P = 0,73).</AbstractText><AbstractText Label="CONCLUSIONES" NlmCategory="CONCLUSIONS">Los resultados de este estudio no apoyan el uso rutinario de metotrexate para el tratamiento de las mujeres cl&#xed;nicamente estables diagnosticadas con un embarazo ect&#xf3;pico tub&#xe1;rico que presenta un nivel s&#xe9;rico bajo la &#x3b2;-hCG (&lt;1500 UI/L). Ser&#xe1;n necesarios estudios adicionales para identificar un subgrupo de mujeres con embarazo ect&#xf3;pico tub&#xe1;rico y &#x3b2;-hCG &#x2265;1500 UI/L para quienes el metotrexate puede ofrecer una alternativa segura y rentable en comparaci&#xf3;n con la cirug&#xed;a. : : ,,&#x3002;&#x3002; : 2005820146,2&#x3002;,,&#x3b2;(beta human chorionic gonadotropin,&#x3b2;-hCG)&lt;1500 IU/L&#x3002;,(50 mg/m<sup>2</sup> )&#x3002;,&#x3b2;-hCG&lt;20 IU/L,&#x3002;&#x3002; : 80,42,38&#x3002;2&#x3001;&#x3001;&#x3001;&#x3b2;-hCG&#x3002;2:83%,76%&#x3002;,[&#x3c7;<sup>2</sup> (1)=0.53;P=0.47]&#x3002;logistic,&#x3b2;-hCG&#x3002;&#x3b2;-hCG,0.15%[,1.0015(95% CI,1.0002~1.003);P=0.02]&#x3002;14&#x3b2;-hCG1000~1500 IU/L,33%,62%&#x3002;,&#x3b2;-hCG&#x3002;,2&#x3b2;-hCG(P=0.73),17.5[(interquartile range,IQR),14~28.0](n=30),14 (IQR,7~29.5)(n=25)&#x3002; : &#x3001;&#x3001;&#x3b2;-hCG(&lt;1500 IU/L)&#x3002;,&#x3b2;-hCG&gt;1500 IU/L&#x3001;&#x3002;.</AbstractText><CopyrightInformation>Copyright &#xa9; 2016 ISUOG. Published by John Wiley &amp; Sons Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Jurkovic</LastName><ForeName>D</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Institute for Women's Health, University College Hospital, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Memtsa</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institute for Women's Health, University College Hospital, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sawyer</LastName><ForeName>E</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Early Pregnancy Unit, Department of Obstetrics and Gynaecology, King's College Hospital, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Donaldson</LastName><ForeName>A N A</ForeName><Initials>AN</Initials><AffiliationInfo><Affiliation>Applied Mathematics &amp; Statistics Department, State University of New York, Stony Brook, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jamil</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Institute for Women's Health, University College Hospital, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schramm</LastName><ForeName>K</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Early Pregnancy Unit, Department of Obstetrics and Gynaecology, King's College Hospital, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sana</LastName><ForeName>Y</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Early Pregnancy Unit, Department of Obstetrics and Gynaecology, King's College Hospital, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Otify</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Early Pregnancy Unit, Department of Obstetrics and Gynaecology, King's College Hospital, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Farahani</LastName><ForeName>L</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Institute for Women's Health, University College Hospital, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nunes</LastName><ForeName>N</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0003-1801-6281</Identifier><AffiliationInfo><Affiliation>Institute for Women's Health, University College Hospital, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ambler</LastName><ForeName>G</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Statistical Science, University College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ross</LastName><ForeName>J A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Early Pregnancy Unit, Department of Obstetrics and Gynaecology, King's College Hospital, London, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>01</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Ultrasound Obstet Gynecol</MedlineTA><NlmUniqueID>9108340</NlmUniqueID><ISSNLinking>0960-7692</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018997">Chorionic Gonadotropin, beta Subunit, Human</NameOfSubstance></Chemical><Chemical><RegistryNumber>YL5FZ2Y5U1</RegistryNumber><NameOfSubstance UI="D008727">Methotrexate</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018997" MajorTopicYN="N">Chorionic Gonadotropin, beta Subunit, Human</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057194" MajorTopicYN="N">Intention to Treat Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016015" MajorTopicYN="N">Logistic Models</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008727" MajorTopicYN="N">Methotrexate</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011247" MajorTopicYN="N">Pregnancy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011274" MajorTopicYN="N">Pregnancy, Tubal</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">expectant</Keyword><Keyword MajorTopicYN="N">methotrexate</Keyword><Keyword MajorTopicYN="N">placebo</Keyword><Keyword MajorTopicYN="N">randomized controlled trial</Keyword><Keyword MajorTopicYN="N">treatment</Keyword><Keyword MajorTopicYN="N">tubal ectopic pregnancy</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>1</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2016</Year><Month>10</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>10</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>10</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>9</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>10</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27731538</ArticleId><ArticleId IdType="doi">10.1002/uog.17329</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>